IF APPROVED, FAMPRIDINE WOULD be the first MS therapy that actually tries to improve nerve function. Other MS drugs -- sold by such companies as Teva Pharmaceutical (TEVA), Biogen Idec (BIIB), Bayer Schering and Pfizer (PFE) -- merely attempt to slow the disease's progress. In fact, it might be used with existing therapies like Bayer Schering's Betaseron. "If approved, Fampridine, would offer those patients who respond to it a rapid, measurable improvement in their walking ability and day-to-day activities that rely on walking," says the 51-year-old Cohen, the son of a neurologist.
Posts You May Be Interested In